Sana Biotechnology (NASDAQ:SANA) Stock Price Down 9.7% After Analyst Downgrade

Key Points

• After Zacks Research downgraded SANA from strong-buy to hold, the stock dropped 9.7%, trading as low as $3.44 on roughly 2.68 million shares (≈19% above average volume).
• Analyst views are mixed but net positive: MarketBeat shows a consensus of “Moderate Buy” with an average price target of $7.83 (seven Buys, one Hold, one Sell).
• Sana, a clinical-stage gene/cell therapy firm, missed quarterly EPS (reported -$0.16 vs. est. -$0.13), has a market cap of about $922M, and roughly 88% institutional ownership.

Sana Biotechnology, Inc. (NASDAQ:SANA - Get Free Report)'s stock price dropped 9.7% during trading on Thursday after Zacks Research downgraded the stock from a strong-buy rating to a hold rating. The stock traded as low as $3.44 and last traded at $3.45. Approximately 2,683,470 shares were traded during mid-day trading, an increase of 19% from the average daily volume of 2,263,731 shares. The stock had previously closed at $3.82.

Several other research analysts also recently issued reports on SANA. Bank of America upped their price target on shares of Sana Biotechnology from $6.00 to $7.00 and gave the stock a "buy" rating in a report on Tuesday, January 6th. Wall Street Zen cut Sana Biotechnology from a "hold" rating to a "sell" rating in a report on Saturday, February 7th. Wedbush increased their target price on Sana Biotechnology from $5.00 to $6.00 and gave the company an "outperform" rating in a research report on Friday, November 7th. Weiss Ratings restated a "sell (e+)" rating on shares of Sana Biotechnology in a report on Monday, December 29th. Finally, HC Wainwright lowered their price objective on Sana Biotechnology from $9.00 to $7.00 and set a "buy" rating for the company in a research note on Wednesday. Seven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $7.83.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in SANA. Nisa Investment Advisors LLC boosted its stake in shares of Sana Biotechnology by 673.8% in the 2nd quarter. Nisa Investment Advisors LLC now owns 10,911 shares of the company's stock valued at $30,000 after purchasing an additional 9,501 shares during the last quarter. Mercer Global Advisors Inc. ADV bought a new stake in Sana Biotechnology during the third quarter valued at $36,000. TD Waterhouse Canada Inc. bought a new stake in Sana Biotechnology during the third quarter valued at $37,000. Lyell Wealth Management LP acquired a new stake in Sana Biotechnology during the 3rd quarter worth about $37,000. Finally, Bay Colony Advisory Group Inc d b a Bay Colony Advisors bought a new position in shares of Sana Biotechnology in the 3rd quarter worth about $39,000. Institutional investors own 88.23% of the company's stock.

Sana Biotechnology Stock Performance

The business has a 50 day moving average price of $4.30 and a 200-day moving average price of $4.14. The company has a market capitalization of $921.64 million, a price-to-earnings ratio of -3.57 and a beta of 1.96.

Sana Biotechnology (NASDAQ:SANA - Get Free Report) last announced its earnings results on Tuesday, March 3rd. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.03). As a group, equities analysts predict that Sana Biotechnology, Inc. will post -1.16 EPS for the current fiscal year.

Sana Biotechnology Company Profile

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company's core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.